Novanta reported second-quarter 2026 results with GAAP revenue of $265.8 million and GAAP diluted EPS of $0.30. Adjusted diluted EPS rose to $0.89 and Adjusted EBITDA increased to $60.7 million. The company said organic revenue grew 9.3% year-over-year and cited the Riverpoint Medical acquisition as immediately accretive.
Financial Highlights
- Revenue (GAAP): $265.8 million for the three months ended July 3, 2026 (up 10.3% year-over-year).
- Gross profit (GAAP): $120.9 million; gross margin (GAAP): 45.5% for the quarter.
- Operating income (GAAP): $18.1 million for the quarter.
- Net income (GAAP): $12.5 million; GAAP diluted EPS: $0.30.
- Adjusted diluted EPS (Non-GAAP): $0.89; Adjusted EBITDA (Non-GAAP): $60.7 million.
Business Highlights
- Organic revenue growth of 9.3% year-over-year, excluding foreign exchange and acquisition effects.
- Segment performance: Automation Enabling Technologies revenue $136.2 million; Medical Solutions revenue $129.6 million.
- Company closed the acquisition of Riverpoint Medical, which management says doubles recurring medical consumables to ~25% of sales on an annualized basis and increases medical end-market exposure to ~60% of revenue.
- Reported strong bookings and a healthy backlog with contributions from new products and disciplined commercial execution in growth end markets.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.